Healthcare organisations should start by identifying every third party that can create, receive, maintain, or transmit protected health information on their behalf. Then they should maintain a current business associate agreement, perform risk assessments based on the services provided, and verify that each partner has a baseline privacy and security programme. Contract language alone is not enough. Ongoing oversight and clear role definitions are essential.
How to structure third-party oversight for protected health information
business associate risk is best managed as an ongoing governance problem, not a one-time contract review. The organisation needs a living inventory of every third party that touches protected health information, plus a clear view of what each party is authorised to do, what data it can reach, and which controls reduce the likelihood of misuse, loss, or inappropriate disclosure.
That framing matters because third-party exposure is usually created by a mix of access scope, data handling, and operational dependence. If the organisation only checks the agreement and not the actual service behaviour, it can miss hidden data flows, subcontractor access, weak security practices, or privileged connections that expand the breach impact.
When the third party is part of a broader platform, integration, or managed service arrangement, the same discipline should apply to downstream providers and subprocessors. The practical question is not just whether the contract exists, but whether the healthcare organisation can describe, monitor, and defend every path by which protected health information is created, stored, processed, or disclosed.
What the business associate agreement does and does not cover
The business associate agreement should define permitted use, disclosure limits, safeguarding obligations, incident notification expectations, return or destruction requirements, and the handling of subcontractors. It is the legal and operational baseline for third-party handling of protected health information, but it is not a substitute for security validation or continuous oversight.
In practice, contract language cannot prove that a partner has implemented access controls, encryption, logging, segregation of duties, or secure offboarding. It also cannot prevent scope creep if the service changes over time. That is why the agreement must be paired with periodic review of service scope, data flows, and control evidence.
For healthcare organisations, the strongest approach is to treat the agreement as one control layer in a wider third-party assurance process. Current guidance suggests using contractual obligations to set expectations, then verifying through risk assessment, security questionnaires, attestations, and issue follow-up that the partner can actually meet those obligations.
How to manage review, monitoring, and escalation over time
Ongoing oversight should be proportionate to the sensitivity of the information and the level of access granted. A low-risk vendor with no direct access to protected health information does not need the same review depth as a revenue-cycle platform, claims processor, or cloud service that stores patient data at scale.
A useful operating model is to tie review frequency to data sensitivity, integration depth, and change activity. Any material change in service scope, subcontractors, hosting model, authentication method, or incident history should trigger reassessment. If a partner cannot demonstrate a baseline privacy and security programme, the organisation should escalate before expanding the relationship or renewing access.
CIS Controls v8 is helpful here because it reinforces the practical controls behind oversight, including account management, access control, logging, and data protection. Those controls are the evidence you want to see when a business associate is handling protected health information on your behalf.
SOC 2 Trust Services Criteria (AICPA) can also support third-party assurance when the vendor already produces an independent report, especially for confidentiality and security expectations. The report does not replace your own risk assessment, but it can reduce blind spots when you need a structured view of the provider’s control environment.
Risk and Threat Considerations
Third-party PHI sharing creates exposure across confidentiality, integrity, and availability. The main risk is not only accidental disclosure, but also overbroad access, weak subcontractor governance, poor offboarding, and control drift when the service changes faster than the oversight process.
Failure mechanism: A business associate may retain unnecessary PHI access, expand data use beyond the original service, or pass PHI to downstream parties without equivalent safeguards. Weak monitoring can leave those conditions in place long after the original approval.
Impact: The organisation can face reportable privacy incidents, breach response costs, contractual disputes, regulatory scrutiny, and patient trust damage. If the third party is operationally embedded, a security failure can also interrupt core care or administrative workflows.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST SP 800-53 Rev 5 sets the technical controls, while ISO/IEC 27001:2022, SOC 2 (AICPA) and GDPR define the regulatory obligations.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST SP 800-53 Rev 5 | AC-20 — Use of External Systems | Third-party PHI sharing depends on controlled external access and use conditions. |
| SA-9 — External System Services | Business associates are external services that require defined controls and assurance. | |
| SR-3 — Supply Chain Controls and Processes | Third-party PHI handling depends on governance of downstream providers and service chains. | |
| Recommendation — Restrict external system access to approved PHI uses and monitor compliance. Define security requirements and monitor external service providers handling PHI. Apply supply-chain controls to third parties and their subcontractors. | ||
| ISO/IEC 27001:2022 | A.5.19 — Information security in supplier relationships | Vendor and business associate oversight is a supplier-security problem. |
| A.5.20 — Addressing information security within supplier agreements | BAAs are the contractual mechanism for PHI safeguards and obligations. | |
| A.5.21 — Managing information security in the ICT supply chain | Third-party PHI exposure often extends through service chains and downstream providers. | |
| Recommendation — Set security requirements for suppliers that process PHI. Include PHI handling, incident notice, and subcontractor obligations in supplier agreements. Assess and control downstream ICT supply-chain risk for PHI services. | ||
| SOC 2 (AICPA) | CC9.2 — Information provided by subservice organizations | Third-party PHI risk includes controls over subcontractors and subservice organisations. |
| CC9.1 — Vendor and Third-Party Risk Management | Business associate oversight is fundamentally third-party risk management. | |
| Recommendation — Evaluate subservice organisation controls that affect PHI processing. Assess vendors that handle PHI and track remediation for control gaps. | ||
| GDPR | Art. 28 — Processor | The processor model closely parallels third-party handling of sensitive personal data. |
| Recommendation — Impose processor terms that require appropriate PHI-equivalent safeguards and oversight. | ||
Practitioner Guidance
What to prioritise: Start with service mapping and access scope before you spend time polishing contract language. If you cannot explain exactly what PHI the third party receives and why, you are not ready to rely on the agreement.
What to verify: Ask for evidence that matches the service, not just a generic security statement. You want to see control ownership, incident notification timing, offboarding handling, subcontractor management, and current privacy and security practices that align with the data actually shared.
Decision rule: If the partner can only offer promises, treat that as insufficient for continued access to PHI. If it can show a baseline programme and ongoing control operation, then periodic reassessment is usually more appropriate than ad hoc review.
Practitioner takeaway: Business associate risk is managed by proving that third-party access is necessary, bounded, and continuously monitored, not by assuming a signed agreement is enough.
Related resources from NHI Mgmt Group
- How should healthcare organisations implement HIPAA safeguards for electronic protected health information across providers and business associates?
- Why does storing Protected Health Information in Office 365 increase compliance and leak risk for healthcare teams?
- What breaks when healthcare organisations do not monitor third-party and business associate access closely?
- Why does vendor risk management matter so much when organisations outsource more business processes to cloud providers and third parties?
Deepen Your Knowledge
Reviewed and updated by the NHIMG editorial team on September 26, 2026.
NHI Mgmt Group — the #1 independent authority on Non-Human Identity, IAM, and Agentic AI security. nhimg.org
